Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 96

1.

Anti-PD-1 Therapy-Associated Perforating Colitis.

Celli R, Kluger HM, Zhang X.

Case Rep Gastrointest Med. 2018 May 31;2018:3406437. doi: 10.1155/2018/3406437. eCollection 2018.

2.

A Serum Protein Signature Associated with Outcome after Anti-PD-1 Therapy in Metastatic Melanoma.

Weber JS, Sznol M, Sullivan RJ, Blackmon S, Boland G, Kluger HM, Halaban R, Bacchiocchi A, Ascierto PA, Capone M, Oliveira C, Meyer K, Grigorieva J, Asmellash SG, Roder J, Roder H.

Cancer Immunol Res. 2018 Jan;6(1):79-86. doi: 10.1158/2326-6066.CIR-17-0412. Epub 2017 Dec 5.

PMID:
29208646
3.

Tumor Microvessel Density as a Prognostic Marker in High-Risk Renal Cell Carcinoma Patients Treated on ECOG-ACRIN E2805.

Jilaveanu LB, Puligandla M, Weiss SA, Wang XV, Zito C, Flaherty KT, Boeke M, Neumeister V, Camp RL, Adeniran A, Pins M, Manola J, DiPaola RS, Haas NB, Kluger HM.

Clin Cancer Res. 2018 Jan 1;24(1):217-223. doi: 10.1158/1078-0432.CCR-17-1555. Epub 2017 Oct 24.

PMID:
29066509
4.

Sarcoidosis Following Anti-PD-1 and Anti-CTLA-4 Therapy for Metastatic Melanoma.

Reddy SB, Possick JD, Kluger HM, Galan A, Han D.

J Immunother. 2017 Oct;40(8):307-311. doi: 10.1097/CJI.0000000000000181.

PMID:
28737620
5.

Nuclear IRF-1 expression as a mechanism to assess "Capability" to express PD-L1 and response to PD-1 therapy in metastatic melanoma.

Smithy JW, Moore LM, Pelekanou V, Rehman J, Gaule P, Wong PF, Neumeister VM, Sznol M, Kluger HM, Rimm DL.

J Immunother Cancer. 2017 Mar 21;5:25. doi: 10.1186/s40425-017-0229-2. eCollection 2017.

6.

Comparing available criteria for measuring brain metastasis response to immunotherapy.

Qian JM, Mahajan A, Yu JB, Tsiouris AJ, Goldberg SB, Kluger HM, Chiang VLS.

J Neurooncol. 2017 May;132(3):479-485. doi: 10.1007/s11060-017-2398-8. Epub 2017 Mar 8.

PMID:
28275886
7.

PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors.

Kluger HM, Zito CR, Turcu G, Baine MK, Zhang H, Adeniran A, Sznol M, Rimm DL, Kluger Y, Chen L, Cohen JV, Jilaveanu LB.

Clin Cancer Res. 2017 Aug 1;23(15):4270-4279. doi: 10.1158/1078-0432.CCR-16-3146. Epub 2017 Feb 21.

PMID:
28223273
8.

From the Guest Editors: Recent Advances and Evolving Challenges in Treating Unresectable Melanoma.

Weiss SA, Kluger HM.

Cancer J. 2017 Jan/Feb;23(1):1-2. doi: 10.1097/PPO.0000000000000244. No abstract available.

9.

Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma.

Daud A, Kluger HM, Kurzrock R, Schimmoller F, Weitzman AL, Samuel TA, Moussa AH, Gordon MS, Shapiro GI.

Br J Cancer. 2017 Feb 14;116(4):432-440. doi: 10.1038/bjc.2016.419. Epub 2017 Jan 19.

10.

Melanoma central nervous system metastases: current approaches, challenges, and opportunities.

Cohen JV, Tawbi H, Margolin KA, Amravadi R, Bosenberg M, Brastianos PK, Chiang VL, de Groot J, Glitza IC, Herlyn M, Holmen SL, Jilaveanu LB, Lassman A, Moschos S, Postow MA, Thomas R, Tsiouris JA, Wen P, White RM, Turnham T, Davies MA, Kluger HM.

Pigment Cell Melanoma Res. 2016 Nov;29(6):627-642. doi: 10.1111/pcmr.12538. Epub 2016 Oct 22. Review.

11.

Evolving Immunotherapy Approaches for Renal Cell Carcinoma.

Curtis SA, Cohen JV, Kluger HM.

Curr Oncol Rep. 2016 Sep;18(9):57. doi: 10.1007/s11912-016-0542-9. Review.

PMID:
27475806
12.

MET Inhibition in Clear Cell Renal Cell Carcinoma.

Xie Z, Lee YH, Boeke M, Jilaveanu LB, Liu Z, Bottaro DP, Kluger HM, Shuch B.

J Cancer. 2016 Jun 18;7(10):1205-14. doi: 10.7150/jca.14604. eCollection 2016.

13.

Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery.

Qian JM, Yu JB, Kluger HM, Chiang VL.

Cancer. 2016 Oct;122(19):3051-8. doi: 10.1002/cncr.30138. Epub 2016 Jun 10.

14.

Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial.

Goldberg SB, Gettinger SN, Mahajan A, Chiang AC, Herbst RS, Sznol M, Tsiouris AJ, Cohen J, Vortmeyer A, Jilaveanu L, Yu J, Hegde U, Speaker S, Madura M, Ralabate A, Rivera A, Rowen E, Gerrish H, Yao X, Chiang V, Kluger HM.

Lancet Oncol. 2016 Jul;17(7):976-983. doi: 10.1016/S1470-2045(16)30053-5. Epub 2016 Jun 3.

15.

PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma.

Nghiem PT, Bhatia S, Lipson EJ, Kudchadkar RR, Miller NJ, Annamalai L, Berry S, Chartash EK, Daud A, Fling SP, Friedlander PA, Kluger HM, Kohrt HE, Lundgren L, Margolin K, Mitchell A, Olencki T, Pardoll DM, Reddy SA, Shantha EM, Sharfman WH, Sharon E, Shemanski LR, Shinohara MM, Sunshine JC, Taube JM, Thompson JA, Townson SM, Yearley JH, Topalian SL, Cheever MA.

N Engl J Med. 2016 Jun 30;374(26):2542-52. doi: 10.1056/NEJMoa1603702. Epub 2016 Apr 19.

16.

Systemic Immunotherapy for the Treatment of Brain Metastases.

Cohen JV, Kluger HM.

Front Oncol. 2016 Mar 9;6:49. doi: 10.3389/fonc.2016.00049. eCollection 2016. Review. No abstract available.

17.

Possible Interaction of Anti-PD-1 Therapy with the Effects of Radiosurgery on Brain Metastases.

Alomari AK, Cohen J, Vortmeyer AO, Chiang A, Gettinger S, Goldberg S, Kluger HM, Chiang VL.

Cancer Immunol Res. 2016 Jun;4(6):481-7. doi: 10.1158/2326-6066.CIR-15-0238. Epub 2016 Mar 18.

18.

Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma.

Bi M, Zhao S, Said JW, Merino MJ, Adeniran AJ, Xie Z, Nawaf CB, Choi J, Belldegrun AS, Pantuck AJ, Kluger HM, Bilg├╝var K, Lifton RP, Shuch B.

Proc Natl Acad Sci U S A. 2016 Feb 23;113(8):2170-5. doi: 10.1073/pnas.1525735113. Epub 2016 Feb 10.

19.

Demonstration of differential radiosensitivity based upon mutation profile in metastatic melanoma treated with stereotactic radiosurgery.

Rutter CE, Johung KL, Yao X, Lu AY, Jilaveanu LB, Yu JB, Contessa JN, Kluger HM, Chiang VLS, Bindra RS.

J Radiosurg SBRT. 2016;4(2):97-106.

20.

Melanoma Brain Metastasis Pseudoprogression after Pembrolizumab Treatment.

Cohen JV, Alomari AK, Vortmeyer AO, Jilaveanu LB, Goldberg SB, Mahajan A, Chiang VL, Kluger HM.

Cancer Immunol Res. 2016 Mar;4(3):179-82. doi: 10.1158/2326-6066.CIR-15-0160. Epub 2015 Dec 23.

21.

Does immunotherapy increase the rate of radiation necrosis after radiosurgical treatment of brain metastases?

Colaco RJ, Martin P, Kluger HM, Yu JB, Chiang VL.

J Neurosurg. 2016 Jul;125(1):17-23. doi: 10.3171/2015.6.JNS142763. Epub 2015 Nov 6.

PMID:
26544782
22.

MET Expression in Primary and Metastatic Clear Cell Renal Cell Carcinoma: Implications of Correlative Biomarker Assessment to MET Pathway Inhibitors.

Shuch B, Falbo R, Parisi F, Adeniran A, Kluger Y, Kluger HM, Jilaveanu LB.

Biomed Res Int. 2015;2015:192406. doi: 10.1155/2015/192406. Epub 2015 Sep 13.

23.

Characterization of tumor infiltrating lymphocytes in paired primary and metastatic renal cell carcinoma specimens.

Baine MK, Turcu G, Zito CR, Adeniran AJ, Camp RL, Chen L, Kluger HM, Jilaveanu LB.

Oncotarget. 2015 Sep 22;6(28):24990-5002. doi: 10.18632/oncotarget.4572.

24.

Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma.

Wilson MA, Zhao F, Khare S, Roszik J, Woodman SE, D'Andrea K, Wubbenhorst B, Rimm DL, Kirkwood JM, Kluger HM, Schuchter LM, Lee SJ, Flaherty KT, Nathanson KL.

Clin Cancer Res. 2016 Jan 15;22(2):374-82. doi: 10.1158/1078-0432.CCR-15-1162. Epub 2015 Aug 25.

25.

Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas.

Krauthammer M, Kong Y, Bacchiocchi A, Evans P, Pornputtapong N, Wu C, McCusker JP, Ma S, Cheng E, Straub R, Serin M, Bosenberg M, Ariyan S, Narayan D, Sznol M, Kluger HM, Mane S, Schlessinger J, Lifton RP, Halaban R.

Nat Genet. 2015 Sep;47(9):996-1002. doi: 10.1038/ng.3361. Epub 2015 Jul 27.

26.

Clinical trials in melanoma patients with brain metastases.

Yushak ML, Chiang VL, Kluger HM.

Pigment Cell Melanoma Res. 2015 Nov;28(6):741-3. doi: 10.1111/pcmr.12401. Epub 2015 Aug 20. No abstract available.

27.

Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab.

McDermott DF, Drake CG, Sznol M, Choueiri TK, Powderly JD, Smith DC, Brahmer JR, Carvajal RD, Hammers HJ, Puzanov I, Hodi FS, Kluger HM, Topalian SL, Pardoll DM, Wigginton JM, Kollia GD, Gupta A, McDonald D, Sankar V, Sosman JA, Atkins MB.

J Clin Oncol. 2015 Jun 20;33(18):2013-20. doi: 10.1200/JCO.2014.58.1041. Epub 2015 Mar 30.

28.

Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites.

Kluger HM, Zito CR, Barr ML, Baine MK, Chiang VL, Sznol M, Rimm DL, Chen L, Jilaveanu LB.

Clin Cancer Res. 2015 Jul 1;21(13):3052-60. doi: 10.1158/1078-0432.CCR-14-3073. Epub 2015 Mar 18.

29.

Identification of novel radiosensitizers in a high-throughput, cell-based screen for DSB repair inhibitors.

Goglia AG, Delsite R, Luz AN, Shahbazian D, Salem AF, Sundaram RK, Chiaravalli J, Hendrikx PJ, Wilshire JA, Jasin M, Kluger HM, Glickman JF, Powell SN, Bindra RS.

Mol Cancer Ther. 2015 Feb;14(2):326-42. doi: 10.1158/1535-7163.MCT-14-0765. Epub 2014 Dec 15.

30.

PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis.

Jilaveanu LB, Parisi F, Barr ML, Zito CR, Cruz-Munoz W, Kerbel RS, Rimm DL, Bosenberg MW, Halaban R, Kluger Y, Kluger HM.

Clin Cancer Res. 2015 May 1;21(9):2138-47. doi: 10.1158/1078-0432.CCR-14-0861. Epub 2014 Oct 14.

31.

PAX-8 expression in renal tumours and distant sites: a useful marker of primary and metastatic renal cell carcinoma?

Barr ML, Jilaveanu LB, Camp RL, Adeniran AJ, Kluger HM, Shuch B.

J Clin Pathol. 2015 Jan;68(1):12-7. doi: 10.1136/jclinpath-2014-202259. Epub 2014 Oct 14.

32.

NY-ESO-1 as a potential immunotherapeutic target in renal cell carcinoma.

Giesen E, Jilaveanu LB, Parisi F, Kluger Y, Camp RL, Kluger HM.

Oncotarget. 2014 Jul 30;5(14):5209-17.

33.

Correlation of somatic mutations and clinical outcome in melanoma patients treated with Carboplatin, Paclitaxel, and sorafenib.

Wilson MA, Zhao F, Letrero R, D'Andrea K, Rimm DL, Kirkwood JM, Kluger HM, Lee SJ, Schuchter LM, Flaherty KT, Nathanson KL.

Clin Cancer Res. 2014 Jun 15;20(12):3328-37. doi: 10.1158/1078-0432.CCR-14-0093. Epub 2014 Apr 8.

34.

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.

Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, Brahmer JR, Lawrence DP, Atkins MB, Powderly JD, Leming PD, Lipson EJ, Puzanov I, Smith DC, Taube JM, Wigginton JM, Kollia GD, Gupta A, Pardoll DM, Sosman JA, Hodi FS.

J Clin Oncol. 2014 Apr 1;32(10):1020-30. doi: 10.1200/JCO.2013.53.0105. Epub 2014 Mar 3.

35.

MEK targeting in N-RAS mutated metastatic melanoma.

Thumar J, Shahbazian D, Aziz SA, Jilaveanu LB, Kluger HM.

Mol Cancer. 2014 Mar 4;13:45. doi: 10.1186/1476-4598-13-45.

36.

PD-L1 Expression in Clear Cell Renal Cell Carcinoma: An Analysis of Nephrectomy and Sites of Metastases.

Jilaveanu LB, Shuch B, Zito CR, Parisi F, Barr M, Kluger Y, Chen L, Kluger HM.

J Cancer. 2014 Jan 24;5(3):166-72. doi: 10.7150/jca.8167. eCollection 2014.

37.

Microvessel area as a predictor of sorafenib response in metastatic renal cell carcinoma.

Aziz SA, Sznol JA, Albiges L, Zito C, Jilaveanu LB, Camp RL, Escudier B, Kluger HM.

Cancer Cell Int. 2014 Jan 14;14(1):4. doi: 10.1186/1475-2867-14-4.

38.

Expression of drug targets in patients treated with sorafenib, carboplatin and paclitaxel.

Jilaveanu LB, Zhao F, Zito CR, Kirkwood JM, Nathanson KL, D'Andrea K, Wilson M, Rimm DL, Flaherty KT, Lee SJ, Kluger HM.

PLoS One. 2013 Aug 6;8(8):e69748. doi: 10.1371/journal.pone.0069748. Print 2013.

39.

Radiation sensitivity and sensitization in melanoma.

Shahbazian D, Bindra RS, Kluger HM, Glazer PM.

Pigment Cell Melanoma Res. 2013 Nov;26(6):928-30. doi: 10.1111/pcmr.12147. Epub 2013 Aug 12. No abstract available.

40.

Advances in the systemic treatment of metastatic melanoma.

Yushak M, Kluger HM, Sznol M.

Oncology (Williston Park). 2013 May;27(5):374-81. Review.

41.

Advances in therapy for melanoma brain metastases.

Flanigan JC, Jilaveanu LB, Chiang VL, Kluger HM.

Clin Dermatol. 2013 May-Jun;31(3):264-81. doi: 10.1016/j.clindermatol.2012.08.008. Review.

PMID:
23608446
42.

Expression of drug targets in primary and matched metastatic renal cell carcinoma tumors.

Aziz SA, Sznol JA, Adeniran A, Parisi F, Kluger Y, Camp RL, Kluger HM.

BMC Clin Pathol. 2013 Feb 1;13:3. doi: 10.1186/1472-6890-13-3.

43.

Vascularity of primary and metastatic renal cell carcinoma specimens.

Aziz SA, Sznol J, Adeniran A, Colberg JW, Camp RL, Kluger HM.

J Transl Med. 2013 Jan 14;11:15. doi: 10.1186/1479-5876-11-15.

44.

Drug targets and predictive biomarkers in the management of metastatic melanoma.

Thumar J, Giesen E, Kluger HM.

Pharmgenomics Pers Med. 2012;5:139-48. doi: 10.2147/PGPM.S25100. Epub 2012 Sep 28.

45.

Studies of NVP-BEZ235 in melanoma.

Sznol JA, Jilaveanu LB, Kluger HM.

Curr Cancer Drug Targets. 2013 Feb;13(2):165-74. Review.

PMID:
23215722
46.

c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma.

Gibney GT, Aziz SA, Camp RL, Conrad P, Schwartz BE, Chen CR, Kelly WK, Kluger HM.

Ann Oncol. 2013 Feb;24(2):343-9. doi: 10.1093/annonc/mds463. Epub 2012 Sep 28.

47.

Vertical pathway targeting in cancer therapy.

Shahbazian D, Sznol J, Kluger HM.

Adv Pharmacol. 2012;65:1-26. doi: 10.1016/B978-0-12-397927-8.00001-4. Review.

PMID:
22959021
48.

Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma.

Krauthammer M, Kong Y, Ha BH, Evans P, Bacchiocchi A, McCusker JP, Cheng E, Davis MJ, Goh G, Choi M, Ariyan S, Narayan D, Dutton-Regester K, Capatana A, Holman EC, Bosenberg M, Sznol M, Kluger HM, Brash DE, Stern DF, Materin MA, Lo RS, Mane S, Ma S, Kidd KK, Hayward NK, Lifton RP, Schlessinger J, Boggon TJ, Halaban R.

Nat Genet. 2012 Sep;44(9):1006-14. doi: 10.1038/ng.2359. Epub 2012 Jul 29.

49.

Driver mutations in melanoma: lessons learned from bench-to-bedside studies.

Mehnert JM, Kluger HM.

Curr Oncol Rep. 2012 Oct;14(5):449-57. doi: 10.1007/s11912-012-0249-5. Review.

50.

Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival.

Knisely JP, Yu JB, Flanigan J, Sznol M, Kluger HM, Chiang VL.

J Neurosurg. 2012 Aug;117(2):227-33. doi: 10.3171/2012.5.JNS111929. Epub 2012 Jun 15.

PMID:
22702482

Supplemental Content

Loading ...
Support Center